Printer Friendly

Sumitomo obtains United States patent.

Sumitomo Pharmaceuticals Company, Limited (Osaka-fu, Japan) has patented semaphorin Y inhibiting neurite outgrowth, and a nucleotide sequence therefor, as well as other Semaphorin sequences hybridizing to the Semaphorin Y sequence, modified proteins or partial peptides of Semaphorin Y, antibodies against Semaphorin Y, antisense nucleotides against Semaphorin Y gene, and the use of such substances as pharmaceutical or diagnostic agents or laboratory reagents are disclosed. Further, a method of screening for Semaphorin Y antagonists employing Semaphorin Y, Semaphorin Y antagonists obtained by the screening method, pharmaceutical agents comprising such antagonists, and transgenic animals involving Semaphorin Y are also disclosed. (US 6,566,094)
COPYRIGHT 2003 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Sumitomo Pharmaceuticals Co.
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:1USA
Date:May 1, 2003
Previous Article:Wisconsin Alumni Research Foundation obtains United States patent.
Next Article:Tularik obtains United States patent.

Related Articles
Patent News.
Patent news.
Patent news.
Sumitomo obtains United States patent.
Dainippon Sumitomo Pharma and Eisai Sign Licensing Agreement for "Gasmotin", a Gastroprokinetic Agent, for Countries in Asia including ASEAN Members.
Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'.
Sumitomo Chemical to Expand Liquid Crystal Polymers Production.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters